This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Fish Oil
Long-chain marine omega-3 (EPA + DHA) — foundational anti-inflammatory + cardiovascular + neural lipid
Aliases (13)
Overview
What is Fish Oil?
Fish oil is the foundational source of long-chain marine omega-3 polyunsaturated fatty acids (n-3 PUFAs) — primarily eicosapentaenoic acid (EPA, C20:5 n-3) and docosahexaenoic acid (DHA, C22:6 n-3). Available OTC as concentrated softgels, liquid, krill oil (phospholipid form), or cod liver oil (with vitamins A+D); available Rx as Lovaza (combined EPA+DHA ethyl esters) and Vascepa/icosapent ethyl (pure EPA-EE) for hypertriglyceridemia. GRAS, FDA-approved Rx forms, and not on the WADA prohibited list. Foundational anti-inflammatory and cardiovascular nutrient.
Key Benefits
Most reproducible: triglyceride reduction (20-30% at 2-4 g/day), membrane anti-inflammatory effect via eicosanoid shift, and pro-resolution signaling via specialized pro-resolving mediators (resolvins, protectins, maresins). Strongest cardiovascular RCT evidence is for pharmaceutical-grade EPA monotherapy (REDUCE-IT, 25% MACE reduction in high-risk statin-treated patients). DHA is the dominant structural fatty acid in synaptic membranes and retinal photoreceptors — supportive for cognitive aging and developmental neurology. Modest depression-adjunct signal at EPA-predominant ratios. For an MMA athlete: high-leverage anti-inflammatory + cardiovascular insurance + brain-membrane support, with ideal pairing to astaxanthin (which protects DHA from peroxidation).
Mechanism of Action
EPA and DHA incorporate into membrane phospholipids at the sn-2 position, displacing arachidonic acid (AA) over weeks. This (1) shifts COX-2 / 5-LOX eicosanoid output from pro-inflammatory 2-series prostaglandins and 4-series leukotrienes toward weaker 3-series PGs and 5-series LTs; (2) provides substrate for specialized pro-resolving mediators (E-series resolvins from EPA; D-series resolvins, protectins, maresins from DHA) that actively resolve inflammation; (3) reduces hepatic SREBP-1c-driven lipogenesis and apo-CIII, lowering VLDL output and triglycerides; (4) modifies membrane fluidity, raft organization, and ion channel kinetics — relevant to cardiac and neuronal function. DHA membrane half-life is ~2-3 weeks (slow turnover); EPA shorter (~1-2 weeks). Steady-state membrane incorporation takes 8-12 weeks of consistent dosing.
Pharmacokinetics
Peptide Interactions
(the V4 stack pairing): Highest-leverage pairing in V4/V5 design. Fish oil provides fat vehicle for astaxanthin absorption (2-4× bioavailability boost); asta…
Foundational lipid-peroxidation chain breaker. Most reputable fish oil products include tocopherols as in-bottle antioxidants. Mixed tocopherols preferred ov…
NAC supports GSH synthesis, sustaining the downstream lipid-peroxide clearance pathway (glutathione peroxidase). Mechanism-aligned with no direct interaction.
Complementary lipid mechanisms — statins lower LDL-C via HMG-CoA reductase inhibition; n-3 PUFAs lower triglycerides via SREBP-1c suppression and apo-CIII re…
Both anti-inflammatory via different mechanisms (n-3 via eicosanoid shift + SPM synthesis; curcumin via NF-κB inhibition). Both fat-soluble; co-administer at…
Both fat-soluble; share the breakfast fat-meal absorption window. No direct biochemical interaction but practical co-stacking.
Mitochondrial-membrane antioxidant. Layered membrane protection. Both fat-soluble.
No interaction. Different mechanisms (n-3 membrane biology vs. ATP buffering). Common stack in athletic populations.
Redundant — krill oil delivers the same EPA+DHA as phospholipids vs. triglycerides. Phospholipid form may have ~1.5× per-gram bioavailability but absolute n-…
Adds vitamins A and D to EPA+DHA; chronic high-dose use risks vitamin A toxicity. Use cod liver oil only if D and A intake are otherwise deficient.
Linoleic acid competes for the same elongation/desaturation enzymes (Δ6/Δ5 desaturase) and shifts membrane phospholipid pool back toward arachidonic acid. Ef…
Quality Indicators
IFOS (International Fish Oil Standards) 5-star certification
Independent third-party batch testing for potency, oxidation (TOTOX), heavy metals (Hg, Pb, Cd), PCBs, and dioxins. The gold-standard quality mark in the fish oil category.
Triglyceride (TG) or re-esterified TG (rTG) form
Native triglyceride form (TG) and reconstituted re-esterified TG (rTG) absorb ~40-70% better than ethyl ester (EE). EE forms are cheaper and common; rTG is the premium absorption format.
Low TOTOX (Total Oxidation) score, ideally <10
TOTOX = 2×Peroxide Value + Anisidine Value. GOED limit is 26; high-quality products are <10. Oxidized fish oil tastes fishy, causes burping, and is pro-inflammatory — opposite of the intended effect.
Stated EPA + DHA mg per softgel (not just '1000 mg fish oil')
A 1000 mg fish oil softgel often contains only 180 mg EPA + 120 mg DHA = 300 mg of the active n-3s. Read the supplement facts panel for actual EPA + DHA mg, not bulk fish oil weight.
Ethyl ester (EE) form
EE form is ~30-50% less bioavailable than TG/rTG and oxidizes faster. Acceptable but suboptimal — choose TG/rTG when budget allows. Most pharmaceutical-grade products (Lovaza, Vascepa) are EE for stability and concentration reasons.
Fishy aftertaste or repeat ('burping')
Indicates oxidation. A fresh, properly stored fish oil should taste clean (or like the lemon/citrus flavoring used to mask). Persistent fishy burping = oxidized batch — return it.
No COA, no third-party testing, generic 'fish oil' label
Unverified products are the highest-risk segment for heavy-metal contamination and oxidation. Avoid bulk-bin no-brand products. Cost difference vs. third-party-tested is small.
Discolored softgels, smell rancid out of the bottle
Visible degradation. Discard and return. Once oxidized, fish oil is pro-inflammatory rather than anti-inflammatory.
What to Expect
- OnsetNo acute felt effect. Plasma fatty acids rise within hours; membrane incorporation takes 2-4 weeks for early effects, 8-12 weeks for steady state. Triglycer…
- Peak/plateau: After 2-3 months of consistent dosing, observable changes are: less joint stiffness, faster DOMS resolution, sometimes skin texture improvement, li…
- TaperMembrane DHA half-life is ~2-3 weeks, so effects fade gradually over 1-2 months after stopping. EPA shorter (1-2 weeks). No withdrawal — just gradual loss o…
Side Effects & Safety
Common (>10% users):
- Fishy aftertaste / burping — often a sign of oxidized batch or empty-stomach dosing. Take with fat-containing meal; refrigerate; switch brand if persistent.
- Mild GI upset, loose stools — usually at >3 g/day or empty stomach.
Less common (1-10%):
- Heartburn / reflux at high dose.
- Mild bleeding-time prolongation (rarely clinically meaningful at <3 g/day).
- Slight metallic / fishy body odor at very high doses.
Rare-serious (<1%):
- Atrial fibrillation at high dose. Dose-dependent AFib signal at ≥2 g/day across REDUCE-IT, STRENGTH, OMEMI. Absolute risk 1-3% over 5 years in older / AFib-predisposed patients. Cap at 1 g/day if AFib history. Not relevant at 20yo with no AFib history.
- Allergic reaction — extremely rare. Possible with shellfish allergy and krill oil specifically (krill = crustacean). Fish body oil is generally tolerated by fish-allergic individuals because the protein allergen is removed during oil refining, but caution warranted.
- Vitamin A toxicity from cod liver oil at chronic high doses.
- Rare hemorrhagic complications at very high dose with concurrent anticoagulants.
Specific watch periods: Pause 5-7 days before elective surgery. Re-check INR within 2 weeks if starting fish oil while on warfarin.
References
Bhatt DL et al. 2018 — REDUCE-IT (icosapent ethyl 4 g/day, NEJM 380:11)
PMID 30415628. 25% MACE reduction in high-risk statin-treated patients. Foundational pure-EPA cardiovascular trial.
View StudyNicholls SJ et al. 2020 — STRENGTH (combined EPA+DHA, JAMA 324:2268)
PMID 33190147. Negative companion to REDUCE-IT; created EPA-vs-DHA debate.
View StudyGISSI-Prevenzione 1999 — EPA+DHA 1 g/day post-MI (Lancet 354:447)
PMID 10465168. Reduced sudden death and total mortality.
View StudyManson JE et al. 2018 — VITAL (n-3 1 g/day primary prevention, NEJM 380:23)
PMID 30415637. Largest primary-prevention n-3 trial; null on primary endpoint with subgroup signals.
View StudyYurko-Mauro K et al. 2010 — MIDAS DHA 900 mg cognitive aging (Alzheimers Dement 6:456)
PMID 20434961.
View StudyMocking RJT et al. 2016 — Meta-analysis n-3 PUFA for MDD (Transl Psychiatry 6:e756)
PMID 26978738. EPA-predominant antidepressant adjunct signal.
View StudySu KP et al. 2018 — Anxiety-symptom n-3 meta-analysis (JAMA Network Open 1:e182327)
PMID 30248536.
View StudyHarris WS et al. 2021 — Blood n-3 levels and mortality in 17 cohorts (Nat Commun 12:2329)
PMID 33850275. Omega-3 index inverse mortality association.
View StudyAbuMweis S et al. 2018 — TG reduction meta-analysis (J Hum Nutr Diet 31:67)
PMID 29574972. 21-23% TG reduction at 2-4 g/day.
View StudyHu Y, Hu FB, Manson JE 2019 — Updated n-3 cardiovascular meta-analysis 13 RCTs (J Am Heart Assoc 8:e013543)
PMID 31567003.
View StudyGencer B et al. 2021 — AFib risk in long-term marine n-3 RCTs (Circulation 144:1981)
PMID 33493993. ~25% relative AFib increase at high dose.
View StudyLombardi M et al. 2022 — Updated AFib meta-analysis (Eur Heart J Cardiovasc Pharmacother)
PMID 34057778.
View StudyCalder PC 2017 — Omega-3 fatty acids and inflammatory processes (Biochem Soc Trans 45:1105)
PMID 28900017. Foundational mechanism review.
View StudySerhan CN 2014 — Pro-resolving lipid mediators (Nature 510:92)
PMID 24899309. Foundational SPM (resolvin/protectin/maresin) review.
View StudyBazan NG 2009 — Neuroprotectin D1-mediated anti-inflammatory and survival signaling (J Lipid Res 50:S400)
Brain DHA-derived SPM mechanism.
View StudyAlbert BB et al. 2015 — Fish oil oxidation in NZ market (Sci Rep 5:7928)
PMID 25638408. 90% exceeded TOTOX limits. Quality-control wake-up.
View StudyIFOS Consumer Reports — International Fish Oil Standards
Third-party batch testing certification.
View StudyGOED Voluntary Monograph — Long-Chain Omega-3 PUFA Quality Standards
TOTOX < 26 industry standard.
View StudyYassine HN et al. 2017 — APOE4 and DHA brain delivery (J Alzheimers Dis 60:1101)
APOE4 carrier DHA brain incorporation impairment.
View StudyMason RP et al. 2020 — EPA vs DHA membrane mechanism differences (Atherosclerosis 296:55)
Plaque stabilization argument for EPA-DHA divergence.
View StudyLatest research
- meta-analysisGencer 2021 — Atrial Fibrillation Risk in Long-Term Marine Omega-3 RCTs~25% relative AFib increase across pooled high-dose n-3 trials. Foundational AFib safety signal — caution at >2 g/day in AFib-predisposed patients.
- meta-analysisHarris 2021 — Blood n-3 fatty acid levels and total / cause-specific mortality from 17 prospective studiesHigher omega-3 index associated with lower all-cause mortality (HR 0.85 top vs bottom quintile across 42,466 individuals).
- rctEffect of High-Dose Omega-3 Fatty Acids vs Corn Oil on MACE (STRENGTH)Combined EPA+DHA carboxylic acid 4 g/day in 13,078 high-risk patients showed NO MACE reduction (HR 0.99). Stopped early for futility. Negative companion to REDUCE-IT — created the EPA-vs-DHA debate.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.